1600

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Sivaram Pillarisetti et al.

Serial No. **10/026,335**

Filed: **December 21, 2001**

For: **Methods and Compositions for Detecting Compounds that Modulate Inflammatory Responses**

1619

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on January 15, 2002.

Janina A. Malone - Reg. No. 47,768

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,



Janina A. Malone
Reg. No. 47,768

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 18631-0121 (45115-264494)

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/026,335
Filing Dat	December 21, 2001
First Nam d Inventor	Sivaram Pillarisetti
Group Art Unit	
Examiner Name	
Attorney Docket Number	18631-0121 (45115-264494)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	AA	Brownlee, M., *et al.*, "Aminoguanidine prevents diabetes-induced arterial w[illegible]otein cross-linking", Science, Vol. 232, pp. 1629-1632, (1986)	
	AB	Brownlee, M., *et al.*, "Nonenzymatic glycosylation and the pathogenesis of di[illegible]complications", Annals of Internal Medicine, Vol. 101, pp. 527-537, (1984)	
	AC	Cohen, M.P., *et al.*, "Role of amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy", Journal of the American Society of Nephrology, Vol. 7, No. 2, pp. 183-190	
	AD	Eitner, F., *et al.*, "Role of interleukin-6 in mediating mesangial cell proliferation and matrix production *in vivo*", Kidney International, Vol. 51, pp. 69-78 (1997)	
	AE	Hofmann, M. A., *et al.*, "RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/Calgranulin polypeptides", Cell, Vol. 97, pp. 889-901 (1999)	
	AF	Horii, Y., *et al.*, "Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis", Kidney International, Vol. 43, Suppl. 39, pp. S-71-S-75, (1993)	
	AG	Huber, S.A., *et al.*, "Interleukin-6 exacerbates early atherosclerosis in mice", Arterioscler. Thromb. Vasc. Biol., Vol. 19, pp. 2364-2367	
	AH	Kado, S., *et al.*, "Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus", Acta. Diabetol., Vol. 36, pp. 67-72, (1999)	
	AI	Lander, H. M., *et al.*, "Activation of the receptor for advanced glycation end products triggers a $p21^{ras}$-dependent mitogen-activated protein kinase pathway regulated by oxidant stress", The Journal of Biological Chemistry, Vol. 272, No. 28, pp.17810-17814 (1997)	
	AJ	Li, Y.M., *et al.*, "Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine", Proc. Natl. Acad. Sci., Vol. 93, pp. 3902-3907 (1996)	
	AK	Morohoshi, M., *et al.*, "The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes", Annals of the New York Academy of Sciences, Vol. 748, pp. 562-570 (1995)	
	AL	Park, L., *et al.*, "Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts", Nature Medicine, Vol. 4, No. 9, pp. 1025-1031 (1998)	
	AM	Piercy, V., *et al.*, "Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: A study with aminoguanidine in C57/BLKsJ diabetic mice", Metabolism, Vol. 47, No. 12, pp. 1477-1480 (1998)	
	AN	Saitoh A., *et al.*, "Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy", Journal of Clinical Laboratory Analysis, Vol 12, pp. 1-5, (1998)	
	AO	Schmidt, A.M., *et al.*, "Activation of receptor for advanced glycation end products", Circulation Research, Vol. 84, pp. 489-497 (1999)	
	AP	Schmidt, A.M., *et al.*, "Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice", Journal of Clinical Investigation, Vol. 96, pp. 1395-1403 (1995)	
	AQ	Soulis, T., *et al.*, "Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment", Kidney International, Vol. 50, pp. 627-634 (1996)	
	AR	Taguchi, A., *et al.*, "Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases", Nature, Vol. 405, pp. 354-360 (2000)	

Examiner Signature		Date Considered	

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet | | of | |

Complete if Known	
Application Number	10/026,335
Filing Date	December 21, 2001
First Named Inventor	Sivaram Pillarisetti
Group Art Unit	
Examiner Name	
Attorney Docket Number	18631-0121 (45115-264494)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	BA	Takagi, M., *et al.*, "Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells", Journal of Bone and Mineral Research, Vol. 12, No. 3, pp.439-446 (1997)	
	BB	Thornalley, Paul J., "Cell activation by glycated proteins AGE receptors, receptor recognition factors and functional classifcation of AGEs", Cellular and Molecular Biology, Vol. 44., No. 7, pp. 1013-1023 (1998)	
	BC	Wada, R., *et al.*, "Only limited effects of aminoguanidine treatment on peripheral nerve function, (Na+, K+)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats", Diabetologia, Vol. 42, pp. 743-747 (1999)	
	BD	Wautier, J.L., *et al.*, "Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy", J. Clin. Invest., Vol. 97, No. 1, pp. 238-243 (1996)	
	BE	Yan, S., *et al.*, "Amyloid-beta peptide-receptor for advanced glycation end product interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease." Proc. Natl. Acad. Sci. U.S.A., Vol. 94, pp.5296-5301 (1997)	
	BF	Yang, C.W., *et al.*, "Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.," Proc. Natl. Acad. Sci. U. S. A., Vol. 91, pp. 9436-40 (1994)	
	BG	Yano M, et al., "Immunohistochemical localization of glycated protein in diabetic rat kidney" Diabetes Res. and Clin. Pract., Vol. 8, pp. 215-219 (1990)	

Examiner Signature		Date Considered	